John A Nyman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7658871/publications.pdf

Version: 2024-02-01

1
36
g-index
1640
1642
citing authors

#	Article	IF	CITATIONS
1	The value of health insurance: the access motive. Journal of Health Economics, 1999, 18, 141-152.	2.7	208
2	Excess Costs and Utilization Associated with Methicillin Resistance for Patients with <i>Staphylococcus aureus</i> Infection. Infection Control and Hospital Epidemiology, 2010, 31, 365-373.	1.8	153
3	The economics of moral hazard revisited. Journal of Health Economics, 1999, 18, 811-824.	2.7	108
4	Is â€~Moral Hazard' Inefficient? The Policy Implications Of A New Theory. Health Affairs, 2004, 23, 194-199.	5.2	96
5	Should the consumption of survivors be included as a cost in cost–utility analysis?. Health Economics (United Kingdom), 2004, 13, 417-427.	1.7	96
6	Quality-of-Life Weights for the US Population. Medical Care, 2007, 45, 618-628.	2.4	80
7	Proactive tobacco treatment offering free nicotine replacement therapy and telephone counselling for socioeconomically disadvantaged smokers: a randomised clinical trial. Thorax, 2016, 71, 446-453.	5.6	63
8	Associations between smoking behaviors and financial stress among low-income smokers. Preventive Medicine Reports, 2015, 2, 911-915.	1.8	40
9	A health economic analysis of clinical islet transplantation. Clinical Transplantation, 2012, 26, 23-33.	1.6	38
10	Cost effectiveness of telecare management for pain and depression in patients with cancer: results from a randomized trial. General Hospital Psychiatry, 2014, 36, 599-606.	2.4	36
11	American Health Policy: Cracks in the Foundation. Journal of Health Politics, Policy and Law, 2007, 32, 759-783.	1.9	34
12	The Effectiveness of a Health Promotion Program After 3 Years. Medical Care, 2012, 50, 772-778.	2.4	31
13	PRODUCTIVITY COSTS REVISITED: TOWARD A NEW US POLICY. Health Economics (United Kingdom), 2012, 21, 1387-1401.	1.7	29
14	More on survival consumption costs in cost-utility analysis. Health Economics (United Kingdom), 2006, 15, 319-322.	1.7	26
15	Something for nothing: A model of gambling behavior. Journal of Socio-Economics, 2008, 37, 2492-2504.	1.0	22
16	The Effectiveness of Health Promotion at the University of Minnesota: Expenditures, Absenteeism, and Participation in Specific Programs. Journal of Occupational and Environmental Medicine, 2010, 52, 269-280.	1.7	19
17	Cost-Effectiveness Analysis of Protected Carotid Artery Stent Placement Versus Endarterectomy in High-Risk Patients. Journal of Endovascular Therapy, 2010, 17, 224-229.	1.5	19
18	The rationale, design, and methods of a randomized, controlled trial to evaluate the effectiveness of collaborative telecare in preserving function among patients with late stage cancer and hematologic conditions. Contemporary Clinical Trials, 2018, 64, 254-264.	1.8	19

#	Article	IF	Citations
19	Costâ€effectiveness of the Collaborative Care to Preserve Performance in Cancer (COPE) trial teleâ€rehabilitation interventions for patients with advanced cancers. Cancer Medicine, 2020, 9, 2723-2731.	2.8	19
20	The welfare economics of moral hazard. , 2001, 1, 23-42.		18
21	A health-economic analysis of porcine islet xenotransplantation. Xenotransplantation, 2010, 17, 233-242.	2.8	18
22	Health insurance theory: the case of the missing welfare gain. European Journal of Health Economics, 2008, 9, 369-380.	2.8	17
23	A Return-on-Investment Analysis of the Health Promotion Program At the University of Minnesota. Journal of Occupational and Environmental Medicine, 2009, 51, 54-65.	1.7	17
24	Cost of screening intensive care unit patients for methicillin-resistant Staphylococcus aureus in hospitals. American Journal of Infection Control, 2011, 39, 27-34.	2.3	17
25	Quality-Adjusted Life Years Lost from Nonfatal Motor Vehicle Accident Injuries. Medical Decision Making, 2008, 28, 819-828.	2.4	15
26	Work and Non-Pathological Gambling. Journal of Gambling Studies, 2013, 29, 61-81.	1.6	13
27	Impact of a workplace physical activity tracking program on biometric health outcomes. Preventive Medicine, 2017, 105, 135-141.	3.4	13
28	The association of consumer cost-sharing and direct-to-consumer advertising with prescription drug useâ~†. Research in Social and Administrative Pharmacy, 2005, 1, 139-157.	3.0	12
29	Cost Recommendations in the Second Edition of <i>Cost-Effectiveness in Health and Medicine</i> Review. MDM Policy and Practice, 2018, 3, 238146831876516.	0.9	12
30	Costâ€effectiveness of populationâ€level proactive tobacco cessation outreach among socioâ€economically disadvantaged smokers: evaluation of a randomized control trial. Addiction, 2019, 114, 2206-2216.	3.3	12
31	Ranolazine Reduces Angina in Women with Ischemic Heart Disease: Results of an Open-Label, Multicenter Trial. Journal of Women's Health, 2019, 28, 573-582.	3.3	12
32	Moral hazard and long-term care insurance. Geneva Papers on Risk and Insurance: Issues and Practice, 2019, 44, 231-251.	2.1	12
33	Measurement of QALYS and the welfare implications of survivor consumption and leisure forgone. Health Economics (United Kingdom), 2011, 20, 56-67.	1.7	11
34	Evaluating Health Insurance: A Review of the Theoretical Foundations. Geneva Papers on Risk and Insurance: Issues and Practice, 2006, 31, 720-738.	2.1	10
35	Decomposition of moral hazard. Journal of Health Economics, 2018, 57, 168-178.	2.7	10
36	Risk Stratification Using Cerebrospinal Fluid Biomarkers in Patients with Mild Cognitive Impairment: An Exploratory Analysis. Journal of Alzheimer's Disease, 2015, 47, 729-740.	2.6	9

#	Article	IF	CITATIONS
37	Cost-effectiveness of enhancing a Quit-and-Win smoking cessation program for college students. European Journal of Health Economics, 2018, 19, 1319-1333.	2.8	9
38	The Effect of Participation in a Fitness Rewards Program on Medical Care Expenditures in an Employee Population. Journal of Occupational and Environmental Medicine, 2012, 54, 280-285.	1.7	8
39	The Economic Impact for Farm Injury in Minnesota, 2004–2010. Journal of Agromedicine, 2016, 21, 171-177.	1.5	8
40	Using Cerebrospinal Fluid Biomarker Testing to Target Treatment to Patients with Mild Cognitive Impairment: A Cost-Effectiveness Analysis. PharmacoEconomics - Open, 2018, 2, 309-323.	1.8	8
41	The 3-Year Disease Management Effect. Journal of Occupational and Environmental Medicine, 2013, 55, 1356-1364.	1.7	7
42	The Effect of Consumer Incentives on Medicaid Beneficiaries' Compliance with Well-Child Visit Guidelines. Inquiry (United States), 2013, 50, 47-56.	0.9	7
43	For What Illnesses Is a Disease Management Program Most Effective?. Journal of Occupational and Environmental Medicine, 2015, 57, 117-123.	1.7	7
44	Effect of Workplace Weight Management on Health Care Expenditures and Quality of Life. Journal of Occupational and Environmental Medicine, 2016, 58, 1073-1078.	1.7	7
45	Cost-effectiveness of spinal manipulation, exercise, and self-management for spinal pain using an individual participant data meta-analysis approach: a study protocol. Chiropractic & Manual Therapies, 2018, 26, 46.	1.5	5
46	The Effect of Recreational Gambling on Health and Well-Being. Eastern Economic Journal, 2021, 47, 29-75.	1.0	4
47	A Theory of Demand for Gambles. SSRN Electronic Journal, 0, , .	0.4	4
48	Continuing Care Retirement Communities and Efficiency in the Financing of Long-Term Care. Journal of Aging and Social Policy, 2000, 11, 89-98.	1.6	2
49	The Effect of Gambling on Health: Evidence from Canada. SSRN Electronic Journal, 2011, , .	0.4	2
50	Affordability of the Health Expenditures of Insured Americans Before the Affordable Care Act. American Journal of Public Health, 2016, 106, 264-266.	2.7	2
51	Including Indirect Medical Care Costs from Survivor Years of Life in Economic Evaluations. Pharmacoeconomics, 2011, 29, 173-174.	3.3	1
52	Mobile Health Intervention to Close the Guidelines-To-Practice Gap in Hypertension Treatment: Protocol for the mGlide Randomized Controlled Trial. JMIR Research Protocols, 2021, 10, e25424.	1.0	1
53	Reevaluating the Evidence for Intensive Postoperative Extracolonic Surveillance for Nonmetastatic Colorectal Cancer. Value in Health, 2022, 25, 36-46.	0.3	1
54	Another Look at Long-Term Care Financing. Health Affairs, 1995, 14, 316-318.	5.2	0

#	Article	IF	CITATIONS
55	Cost of Medicare for All: Review of the Estimates. Applied Health Economics and Health Policy, 2021, 19, 453-461.	2.1	O
56	Price and quality transparency: how effective for health care reform?. Minnesota Medicine, 2009, 92, 32-5.	0.1	O